The results showed that similar to the effects of RUNX1 expression in luminal cancers, elevated expression of DDR1 associated with increased survival in non-triple negative breast cancers (ER+/PR+/HER2+) (Figures 6Ci and 6Cii). Here, DDR1 is linked to cancer.